Hyperion DeFi (HYPD) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
5 May, 2026Executive summary
Annual Meeting scheduled virtually for June 30, 2026, at 12:00 p.m. Eastern Time.
Proxy materials and annual report for year ended December 31, 2025, are available online.
Stockholders can attend, vote, and request materials using an 11-digit Control Number.
Voting matters and shareholder proposals
Election of five directors for one-year terms expiring in 2027 or until successors are elected.
Ratification of CBIZ CPAS P.C. as independent auditor for fiscal year ending December 31, 2026.
Advisory vote on executive compensation for named executive officers.
Amendment to Certificate of Incorporation to allow stockholder action by written consent.
Proposal to adjourn the meeting if more time is needed for Proposal 4.
Board of directors and corporate governance
Board recommends voting "FOR" all director nominees and all proposals.
Director nominees: Hyunsu Jung, Michael Geltzeiler, Rachel Jacobson, Happy Walters, Ellen Strahlman, M.D.
Latest events from Hyperion DeFi
- Record Q2 net income and EBITDA driven by HYPE growth, DeFi ramp, and cost discipline.HYPD
Q2 2026 - Q1 2026 net income $8.8M, adjusted gross profit up 17%, guidance raised to $5M–$7M.HYPD
Q1 2026 - Five key proposals, governance updates, and major transactions highlighted for the 2026 meeting.HYPD
Proxy filing - Five key proposals, governance updates, and compensation details set for the 2026 annual meeting.HYPD
Proxy filing - Q4 adjusted gross profit jumped 87% QoQ, with 2026 guidance targeting 4x FY 2025 results.HYPD
Q4 2025 - All recent capital is used to build a HYPE token reserve, exposing the business to crypto volatility.HYPD
Registration Filing - Shelf registration allows up to $100M in offerings, including $25M at-the-market sales via Leerink Partners.HYPD
Registration Filing - Q3 net loss was $7.9M as clobetasol launched, MydCombi expanded, and liquidity risks persisted.HYPD
Q3 2024 - Q2 net loss rose to $11.1M as cash fell and late-stage ophthalmic programs advanced.HYPD
Q2 2024